RenovoRx (RNXT) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
RenovoRx (RNXT) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, gaining 18.3% versus a loss of 85.2%. Over five years, RNXT leads with a -85.3% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($46.2 million vs $45.5 million), about 1.0 times the size, while RenovoRx is growing revenue faster (+2511.6% vs +29.8%).
Tonix Pharmaceuticals converts more of its revenue into profit, with a net margin of -946.2% versus -994.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNXT | TNXP |
|---|---|---|
| Share price | $0.942 | $2.38 |
| Market cap | $45.45M | $46.25M |
| 1-day change | -10.29% | -6.67% |
| YTD return | +12.14% | -84.76% |
| 1-year return | +18.34% | -85.22% |
| 5-year return | -85.26% | -100.00% |
| EPS (TTM) | $-0.31 | $-12.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.12M | $13.11M |
| Revenue growth (YoY) | +2511.63% | +29.85% |
| Net income (latest FY) | $-11.17M | $-124.02M |
| Gross margin | 70.88% | 49.34% |
| Operating margin | -1113.98% | -959.05% |
| Net margin | -994.48% | -946.22% |
| 52-week high | $2.59 | $20.56 |
| 52-week low | $0.77 | $2.30 |
| Distance from 52-week high | -63.63% | -88.42% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +656.90% | +1769.75% |
| Average volume | 815.75K | 838.83K |
| Shares outstanding | 48.25M | 19.43M |
| Employees | 17 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed TNXP by 103.6 percentage points over the past year.
- Tonix Pharmaceuticals is more profitable, keeping -946.2 cents of every revenue dollar as net income versus -994.5 cents for RenovoRx.
- RenovoRx grew revenue faster in its latest fiscal year (+2511.63% vs +29.85%).
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
RNXT vs TNXP FAQ
Which is bigger, RenovoRx or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $46.25M compared with $45.45M for RenovoRx (RNXT).
Which stock has performed better over the past year, RNXT or TNXP?
RNXT returned +18.34% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are RenovoRx and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.